Pancreatic cancer patients face a poor prognosis, partly due to their inadequate response to current standard-of-care chemotherapies and the development of acquired resistance. This resistance and the response to chemotherapy are influenced by signaling and metabolic changes in tumor cells and alterations in the immune and non-immune stroma.
The Pancreatic Cancer ARTNet Center (PCAC)aims to address these challenges by integrating research on metabolic and signaling mediators of acquired resistance and stromal remodeling to develop effective therapies and improve patient outcomes. The Center's objectives include understanding the signaling responses of cancer cells and stroma, investigating metabolic adaptations, developing novel therapeutic combinations, and coordinating research efforts. This will be achieved through the following specific aims:
(1)
Investigate novel mechanisms of acquired resistance at the tumor-stromal metabolic interface.
(2)
Provide innovative tools and resources to study and validate these mechanisms.
(3)
Facilitate a systems-level understanding of acquired therapy resistance.
The Principal Investigator of PCAC is Dr. Pankaj K. Singh.
(For additional information, please visit NIH RePORTER)
